Articles tagged with Liver Tumors
A cohort study evaluates histotripsy's short-term outcomes for liver tumors, highlighting its potential as a treatment option. The study also examines national practice patterns and adult patient results.
A Singapore team developed a machine-learning tool that accurately predicts liver cancer recurrence after surgery, outperforming the TNM staging system. The tool identifies two biologically distinct patterns of recurrence, enabling personalized approaches to risk prediction and targeted therapies.
A Johns Hopkins Medicine team created a computational model to forecast which patients with hepatocellular carcinoma (HCC) will benefit from combination treatment using immunotherapy and targeted therapy. The spatial QSP modeling platform accurately predicted response rates for virtual patients, demonstrating its potential to inform pe...
Researchers at UCL and Great Ormond Street Hospital have successfully treated a deadly childhood liver disease using mice with a healthy version of the VPS33B gene. The treatment, which specifically targeted liver cells, showed no harm and improved liver function in mice.
CPSS cause hyperammonemia, hepatopulmonary syndrome, portopulmonary hypertension, and liver nodules/tumors. Detection relies on Doppler ultrasound, CT angiography, and MRI. Treatment depends on shunt type and severity, with endovascular or surgical options available.
Researchers found that tumor-associated macrophages produce acetate through a metabolic interaction involving lactate and the lipid peroxidation–ALDH2 pathway. This acetate promotes histone H3 acetylation and epithelial-mesenchymal transition in hepatocellular carcinoma cells, enhancing metastasis.
Researchers have discovered myeloid cells in children's liver tumors that could be activated for treatment. This discovery provides new avenues for immunotherapy in childhood liver cancer.
Researchers investigated tirzepatide's therapeutic efficacy on MASLD, a complex liver disease characterized by abnormal lipid accumulation and inflammation. Tirzepatide alleviated hepatic steatosis in mouse models by enhancing lipolysis and reducing lipid uptake through the regulation of CD36 and OBP2A.
Researchers at Purdue University have developed a new method to study biochemical processes that impair the immune system's ability to recognize and kill cancer cells. The method involves tracking RNA-binding proteins and extracellular vesicles, which can compromise immunotherapy.
Researchers found Galectin-1, a sugar-binding protein, plays a critical role in helping hepatocellular carcinoma cells resist thermal ablation and thrive after being treated with high heat. Blocking Gal-1 can make thermal ablation more effective and reduce the risk of recurrence.
The ESMO Gastrointestinal Cancers Congress 2025 will cover topics such as molecular prevention and precision therapy, patient-centred approaches and quality of life. Key findings include the efficacy and safety of combined immunotherapy for hepatocellular carcinoma and colorectal cancer.
Researchers at Thomas Jefferson University found that VDAC2, a mitochondrial protein, can make liver cancer cells more vulnerable to existing treatments targeting BAK-dependent cell death. The study suggests that combining pre-clinical drugs targeting BAK could shrink tumors in mice with high levels of VDAC2.
The study found that serum-derived hsa_circ_101555 showed excellent diagnostic accuracy in differentiating HCC patients from healthy controls. It also demonstrated a prognostic role in predicting tumor progression and response to therapy, with significant correlations with markers of liver inflammation and tumor features.
Researchers found that blocking the activity of a protein called erythropoietin (EPO) turns formerly 'cold' liver tumors into 'hot' tumors teeming with cancer-fighting immune cells. The treatment led to complete regression of existing liver tumors in most mice, outperforming immunotherapy alone.
Hepatocellular carcinoma is the most prevalent form of liver cancer, and liver transplantation offers a curative treatment option for appropriately selected patients. Bridging therapies, such as radiofrequency ablation and transarterial chemoembolization, can improve survival outcomes post-transplant by preventing tumor progression.
A multicenter retrospective study found that routine caudate lobe resection does not significantly improve long-term survival and recurrence for patients with HCCA. However, achieving a negative margin is crucial for improving prognosis.
A new editorial in Oncotarget discusses how artificial intelligence can improve liver imaging by recognizing when it might be wrong. The approach, called 'uncertainty quantification,' helps clinicians better detect liver cancer and other diseases by pointing out areas in medical scans that need a second look.
GTF3C2 expression is upregulated in HCC tissues, promoting tumor growth and poor survival outcomes. The GTF3C2/USP21/MEK2/ERK1/2 pathway regulates HCC cell proliferation and tumor growth.
A new editorial highlights a growing concern in cancer care: radiotherapy may leave behind residual disease that can lead to worse long-term outcomes. Studies have shown that patients with residual disease are more likely to experience cancer recurrence and shorter survival, emphasizing the need for regular biopsy-based tests.
Researchers used CRISPR to cut a single gene from cancer cells of head and neck tumors, resulting in the elimination of 50% of the tumors after 84 days. This groundbreaking study demonstrates that some genes are essential for cancer cell survival, making them excellent targets for CRISPR therapy.
Recent developments in fluorescent probes offer improved specificity and sensitivity for detecting hepatocellular carcinoma (HCC). Next-generation probes are being developed to enhance tissue penetration depth and probe specificity, potentially improving surgical outcomes.
Hepatic biliary adenofibroma (BAF) is a rare, benign tumor with histological characteristics distinct from other biliary tumors. Emerging case reports suggest potential for malignant transformation and overlap with intrahepatic cholangiocarcinoma (iCCA), highlighting diagnostic challenges and need for further research.
Researchers at UCSF have identified unique, cancer-specific proteins created through mistakes in RNA splicing. These antigens could be used to create potent immunotherapies that recognize and attack hard-to-treat tumors. The discovery offers new hope for glioma patients and expands the number of targets available for cancer therapy.
Researchers at Rockefeller University have discovered a distinct transcriptomic signature for fibrolamellar hepatocellular carcinoma, a rare and aggressive form of liver cancer. The study's findings may lead to improved detection and treatment options for patients.
Researchers at UMass Amherst have developed a non-toxic bacterial therapy, BacID, to deliver cancer-fighting drugs directly into tumors. The therapy uses genetically engineered strains of Salmonella that can target tumors and control the release of cancer-fighting drugs inside cancer cells.
Scientists at Salk Institute discovered that removing bile acid-creating protein BAAT and adding bile acid UDCA controls tumor growth in mice with liver cancer. UDCA supplements may be a quick solution to improving liver cancer patient outcomes.
Research suggests that T-cell receptor repertoire analysis can inform treatment responses and predict efficacy in combination therapies for HCC. Advances in sequencing technologies are refining our understanding of tumor-immune interactions and adaptive immune mechanisms.
Researchers found that tumor cell secreted DNA in extracellular vesicles acts as a 'danger' signal to activate an anti-tumor response in the liver, reducing liver metastasis risk. The discovery improves understanding of cancer progression and anticancer immunity.
Researchers discovered that cancer grows uniformly throughout its mass, with every region equally active and potentially harboring aggressive mutations. This finding challenges the traditional 'two-speed' entity model of tumors, where rapidly dividing cells on the surface and slower activity in the core were thought to exist.
This review provides a comprehensive overview of CTC detection methods, their association with HCC progression, and their role in prognostication and treatment monitoring. Studies show that the number of CTCs correlates with tumor size, grade, and overall cancer severity.
Researchers identified a previously unknown form of lymph node-like structures in liver tumors that are associated with greater treatment response and lower recurrence rates. The structures, found in patients treated with immune checkpoint inhibitors, contain infection-fighting immune B cells and tumor-killing immune T cells.
Researchers found that WNTinib significantly delayed tumour growth and extended survival in mice with hepatoblastoma cells harboring CTNNB1 mutations. The treatment also showed promise in shrinking tumors in patients' tumor tissue models, with some tumors disappearing completely.
A research team led by Prof. ZHOU Rongbin found that GPR34 promotes tumor growth by suppressing ILC1-mediated anti-tumor activity. Blocking GPR34 with inhibitors can inhibit tumor growth in various models, providing a new immunotherapy strategy for liver and colorectal cancers.
Researchers at Weill Cornell Medicine have discovered a biomarker that can predict which patients with liver cancer are likely to benefit from immunotherapy. The study found that high levels of the immune-suppressing protein NBR1 may identify patients who will not respond to treatment, while lowering NBR1 levels may help shrink tumors.
Researchers at VCU Massey Comprehensive Cancer Center are exploring a new approach to treating liver cancer using immunotherapy and a newly developed drug that inhibits the MYC gene. The four-year grant aims to identify effective treatment combinations for hepatocellular carcinoma, improving patient survival rates.
A new study has found that using a higher dosage of radioembolisation treatment with yttrium-90 microspheres can improve overall survival outcomes for liver cancer patients. Patients who received this elevated dose had significantly better results, with some experiencing prolonged survival and even curative treatments.
A cancer vaccine demonstrated its effectiveness when administered at an early stage, preventing tumor progression and achieving long-term protection. The study's findings support further investigation into personalized vaccines for cancer treatment.
Scientists at RIKEN CPR created a method to change albumin's molecular ID card, allowing for targeted treatments against diseases like cancer. The new technology can transport proteins out of the body, mimicking drug delivery and removal.
The #HOPE4LIVER trial demonstrated the safety and efficacy of histotripsy as a treatment for primary and metastatic liver tumors, achieving a 95% technical success rate. The procedure's non-invasive nature and ability to spare critical vessels and bile ducts offer promising alternatives to traditional treatments.
Researchers explore emerging role of Graph Filtration Learning (GFL) in revolutionizing HCC imaging analysis. GFL captures complex topological features inaccessible to traditional pixel-based methods.
The Chinese College of Interventionalists has introduced a consensus statement on TACE refractoriness in hepatocellular carcinoma, providing a framework for clinicians to identify and manage the condition. This move aims to optimize treatment strategies and improve patient outcomes, particularly in China where HCC incidence is high due...
Cancer cells can attach themselves to liver cells when specific proteins are present, allowing them to colonize and form new tumors. This discovery provides insights into the metastatic process and may lead to potential treatments that prevent cancer from establishing new tumors.
Researchers explore various immunotherapies, including immune checkpoint inhibitors and adoptive cell therapies, as promising treatments for hepatocellular carcinoma. The review aims to overcome current limitations of targeted therapies by regulating the body's immune systems.
Researchers have identified microproteins exclusive to liver tumors that can stimulate the immune system against cancer cells. These small molecules, generated from previously non-coding genes, could be used to develop new treatments, including vaccines that stop or reduce tumor growth.
Researchers found that regorafenib synergizes with TAS102 to inhibit cancer growth, angiogenesis, and microvessel density in preclinical models of colorectal and gastric cancers. The combination also suppresses ERK1/2 activation regardless of KRAS or BRAF mutational status.
Researchers identified nidogen-2 as a key driver of pancreatic cancer progression and metastasis. Blocking this molecule enhanced chemotherapy effectiveness and reduced spread in mouse models, suggesting a promising new treatment approach.
Immunotherapies have revolutionized HCC treatment by enhancing the immune system's ability to recognize and destroy cancer cells. Key approaches include checkpoint inhibitors, targeted therapies, and advanced cellular immunotherapies.
A recent study published in Journal of Hepatology found that over 40% of liver cancer samples harbor more than one molecular subtype, leading to a
Researchers discuss primary hepatic angiosarcoma, a rare mesenchymal liver tumor, and its poor prognosis compared to hepatocellular carcinoma. Diagnosing PHA is critical due to its similar clinical presentation to HCC.
Researchers found that ARID1A mutation renders tumors sensitive to immunotherapy by triggering an antiviral immune response. This could lead to improved patient outcomes and the development of targeted therapies.
Researchers have developed a new treatment that uses tailored doses of anti-cancer drugs released directly into the surgical cavity to treat liver cancer. The approach has shown promise in reducing recurrence rates and minimizing chemotherapy side effects, with potential applications for other types of cancer.
Researchers developed a nanosized polymer that selectively delivers chemotherapeutic drugs to blood vessels supporting tumor growth. The treatment eliminates colorectal cancer liver metastases and prolongs mice survival after a single dose-therapy.
A faulty beta-catenin gene helps tumours evade immunity by stopping tumor cells releasing message-containing cargoes called exosomes. Silencing mutant-beta-catenin could be a viable therapeutic strategy to trigger immune cell infiltration and increase tumour-to-immune cell communication.
Rockefeller University researchers have discovered a new way to target the oncogene behind a rare and often deadly liver disease using small interfering RNAs (siRNAs). The approach involves delivering siRNAs inside fibrolamellar hepatocellular carcinoma (FLC) cells through a surface receptor, blocking the oncogene from producing illnes...
Scientists at Johns Hopkins have developed a novel approach to identify cancer-causing repeats in DNA sequences, enabling non-invasive detection and monitoring of cancers. The ARTEMIS method uses machine learning to analyze cell-free DNA and distinguish between tumor and normal tissues with high accuracy.
A University of Cincinnati study found real-time navigation enhances precision in liver cancer ablation, with improved accuracy for less experienced surgeons. The technology provides detailed information on tumor location, reducing damage to surrounding healthy tissue.
A study by UC Davis Health found that a single dose of BCG reduced liver tumor burden and extended the survival of mice with liver cancer. The vaccine boosted the body's immunity, leading to tumor shrinkage and improved liver function.
Korea University researchers found that perioperative radiotherapy significantly improves survival rates among HCC patients at high risk of recurrence. The study suggests that radiotherapy can reduce recurrence and improve survival in these patients, providing a significant adjuvant treatment option.
A recent study discovered a causal link between oncofoetal ecosystems and liver cancer recurrence, highlighting their potential as biomarkers for treating hepatocellular carcinoma (HCC). The research found that oncofoetal reprogramming contributes to EMT, tumour cell proliferation, and response to immunotherapy.
A team of researchers from MIT and the Broad Institute developed two types of injectable molecules called 'priming agents' that can boost DNA levels in blood samples, allowing for earlier cancer diagnosis and more sensitive detection of tumor mutations. The approach could also help improve detection of cancer recurrence.